|Dr Tariq Ahmad is a Consultant Gastroenterologist at the Royal Devon and Exeter NHS Foundation Trust, Lead Clinician for the Exeter Inflammatory Bowel Disease (IBD) Service and Honorary Associate Professor at the University of Exeter Medical School. He is the elected UK representative of the European Crohn’s and Colitis Organisation, medical advisor to Crohn’s & Colitis UK and a member of the NHS England and Genomics England Joint Pharmacogenomics Working Group.
Dr Ahmad studied medicine at the University of Bristol and obtained a doctorate from the University of Oxford on the genetics of IBD. Dr Ahmad integrates translational research and clinical trials with clinical practice. The Exeter IBD research group focusses on the development and implementation of genetic and serological tests to allow individualised treatment strategies for patients with IBD. Dr Ahmad is the chief investigator of PRED4 (www.ibdresearch.co.uk) which has led to actionable pharmacogenetic findings, and PANTS (https://pantsdb.co.uk) which has driven the rapid adoption of biologic monitoring into UK practice. Dr Ahmad has been awarded numerous research grants and has published widely in major peer-reviewed journals.
Jakob Benedict Seidelin
|Jakob Seidelin has a Medical Degree (MD), a PhD and DMSc from Copenhagen University and is Associate Research Professor in Gastroenterology at Herlev Hospital, University of Copenhagen. He is a consultant in Gastroenterology with focus on IBD and is head of the clinical research unit and responsible for the treatment of immune check-point inhibitor induced colitis at Herlev Hospital. His main research interests are wound healing mechanisms of the intestine and regenerative medicine in IBD as well as clinical trials in IBD. He is national representative of the United European Gastroenterology (UEG).|
|Professor Annika Bergquist is a researcher at Karolinska Institutet Stockholm, Sweden. She received her PhD from the Karolinska Institutet (KI) in 2001 with the thesis “Cholangiocarcinoma in PSC”. And became adjuct professor at KI in 2013 and is currently being a consultant in Hepatology at the Karolinska University Hospital, with a special interest in autoimmune liver diseases. She is leading the research group at KI and Karolinska University Hopsital and is the Chair of the national research network for liver disease (www.swehep.se). The research focus is on clinical studies and biomarkers in PSC.|
|Jørn Brynskov MD, DMSc is Consultant Gastroenterologist at the Department of Gastroenterology at Herlev-Gentofte University Hospital, Copenhagen, Denmark and head of the G-I and Inflammatory Bowel Disease Section. He graduated from the University of Copenhagen, Faculty of Medicine in 1981 and was appointed Medical Doctor of Science (MDSci) (1994) in IBD immunology. He has been a member of the Central Scientific Board, Herlev-Gentofte University Hospital for more than a decade and served as a National representative in the European Crohn’s and Colitis Organisation (ECCO). Besides that, he is an Editor for Scandinavian Journal of Gastroenterology. The publication list encompasses, as of November 2019, a total of 126 papers indexed in PubMed; the vast majority being original work in the field of inflammatory bowel disease, notably studies of immunology, the role of cytokines in blood and bowel mucosa, including epithelial cells. Dr. Brynskov has also been involved in several international clinical trials on immunosuppressive treatments, including biological treatment. Currently, the scientific focus is on optimising the clinical effect and usefulness of biologic and immunosuppressive treatments in patients with IBD, including the development of drug-specific, structured treatment schemes, known as “timelines”, as well as PROs. Dr Brynskov has been supervisor for several medical students and Ph.D.’s as well as two Doctoral Thesis’ in the field of IBD.|
|Christianne Buskens graduated at the Medical School at the University of Utrecht in 1999. From 2000 until 2003 she worked as a research fellow at the department of surgery, and the department of experimental oncology at the Academic Medical Centre (AMC) in Amsterdam. This resulted in her PhD thesis ´The development of new treatment strategies for oesophageal cancer’, which she defended with distinction in 2004. She was trained as a surgeon from 2003 until 2009 at the AMC, Antoni van Leeuwenhoek Hospital (Amsterdam), and Gelre Hospitals (Apeldoorn). After completion of her surgical training, she was granted a fellowship from the Dutch Cancer Organization (KWF) at the department of colorectal surgery in Oxford, United Kingdom. Here, she specialized in proctology and minimally invasive surgery. In January 2012, she became a staff member of the AMC colorectal surgeons group. Nowadays, she combines her clinical work as an IBD surgeon with translational research which is funded by an innovative research incentive grant from The Netherlands organisation for health research and development. Her research lines focus on the role of the appendix in ulcerative colitis, and the the effector functions of (myeloid) immune cells. She also has a masters in clinical epidemiology.|
Anthony de Buck van Overstraeten
|Anthony de Buck van Overstraeten obtained his medical degree at the University of Leuven in Belgium, where he completed his surgical and colorectal training. In 2013 he completed a colorectal fellowship at Mount Sinai Hospital in Toronto. He then returned to Belgium and after 4 years as a colorectal surgeon at the University Hospital of Leuven in Belgium, he moved to Toronto in 2017 where he is an Assistant Professor in the Department of Surgery at the University of Toronto, and a colorectal surgeon in the Department of Surgery at Mount Sinai Hospital. He has a Master’s Degree in Clinical Epidemiology from the University of Toronto. His scientific work focusses on clinical outcome research, mainly situated in the field of IBD, and specifically focussing on functional and quality of life outcomes in IBD patients, including the impact of minimally invasive surgery on clinical outcome.|
|Geert D’Haens is Professor of gastroenterology at the Academic Medical Center at the University of Amsterdam where he leads the IBD Unit. After graduation at the University of Leuven, Belgium, he was trained in gastroenterology, gastrointestinal endoscopy and inflammatory bowel diseases at the University Hospitals in Leuven and at the University of Chicago Hospitals under the mentorship of Paul Rutgeerts and Steven Hanauer, respectively. He finished his PhD thesis in 1996 on mechanisms causing postoperative recurrence of Crohn’s disease. After that, most of his research efforts went into the mechanism of action of new IBD drugs, the development of endoscopic endpoints and surrogate markers for IBD and the effect of early intervention with anti-TNF. In 1999, he was co- founder of ECCO, the European Crohn’s and Colitis Organization. Currently, D’Haens leads a group of more than 35 IBD researchers in the AMC. He is also Medical Director of Robarts Clinical Trials in Europe and former chairman of IOIBD, the international organization for study of IBD. He authored more than 400 peer reviewed articles so far and participates in many drug development programs and clinical trials for IBD.|
|Michael Eberhardson has a Medical Degree (MD) and a PhD (in Medical Cell Biology) from Uppsala University and is Associate Professor in Gastroenterology at Karolinska Institutet. He is a consultant in Gastroenterology with focus on IBD and medical lead of the Gastro Research Unit at Danderyd Hospital. He also serves part time at the Department of Clinical Immunology, Karolinska University Hospital. Dr Eberhardson has a special interest in immunological monitoring of IBD. He is a member of the board of the Swedish Organisation for the Study of IBD (SOIBD) and a member of the steering committee of the National Quality Registry for Inflammatory Bowel Disease (SWIBREG). He is elected national representative of the European Crohn’s and Colitis Organisation (ECCO).|
|Martti Färkkilä is a professor of gastroenterology at Helsinki University and head of Clinic of Gastroenterology at Helsinki University Hospital (HUH). His main interests are treatment of viral hepatitis, cholestatic liver diseases, especially PSC and inflammatory bowel disease. He has been responsible for the treatment guidelines for HCV and HBV at HUCH. He has supervised 15 PhD students and published more than 220 orginal papers.|
|Jonas Halfvarson is a Consultant Gastroenterologist specialising in IBD at Örebro University Hospital, Sweden. He graduated as MD at Uppsala University, Sweden, before training in gastroenterology at Örebro University Hospital. He undertook research with Professor Gunnar Järnerot and obtained his PhD, entitled ‘Inflammatory bowel disease in twins; Studies of genetics and environmental factors’ in 2004. Part of his PhD was done at the University of Oxford, UK with Professor Derek Jewell. Today his research focuses on biomarkers in IBD, both from a clinical and from a mechanistic perspective. He has published over 130 peer-reviewed full papers, as well as contributed to several books on IBD. He has served as vice director for the Swedish national PhD and Postdoctoral program for translational gastroenterology and heads the taskforce for genetics and pathophysiology at the Swedish Organisation for the Study of IBD. Today he is appointed Professor at Örebro University and combines his time in clinical practice with his positions at the University. Dr Halfvarson was named a Rising Star in Gastroenterology at the United European Gastroenterology (UEGWeek) in 2011 and is a member of the International Organization for the study of Inflammatory Bowel Disease (IOIBD) since 2014.|
|Susanna Jäghult works as an IBD nurse since many years. She got her PhD in 2012 and her thesis was about "Living with inflammatory disease - HRQOL, worries and stress". Susanna is one of the founders of the Swedish Nurse Association and has been the chaiman for many years. She is also a member of the N-ECCO Committee and is responsible for the Research Forum. Susanna is working at the Stockholm Gastro Center and is in charge of the unit at Odenplans läkarhus.|
|Lars-Petter Jelsness-Jørgensen is professor of health sciences at Østfold University College, and senior researcher at Østfold Hospital Trust in the southeastern part of Norway. Following education in history, ethnology and psychology at the Universities of Trondheim and Oslo, he went on to study nursing at Oslo Metropolitan University. He furthermore completed his masters degree within the field of patient reported outcome research in 2009, and his ph.d. under the supervision of professor Bjørn Moum, at the institute of clinical medicine, University of Oslo, in 2011. Jelsness-Jørgensens ph.d. focused on prevalence, predictors and consequences of IBD-related fatigue. Following his ph.d he has continued his research within the field of IBD. He is furthermore still working in a clinical position at the department of gastroenterology, Østfold Hospital Trust.|
|Jan Marsal works at Skåne University Hospital and Lund University in Lund and Malmö, Sweden. He is a Consultant Gastroenterologist focusing on IBD and runs a research group with six PhD-students, exploring various aspects of IBD, from basic immunology, through translational questions, to clinical issues. He has defended a basic science thesis in the field of immunology after 6 years of laboratory work, including 14 months as a Visiting Research Fellow at Harvard Medical School, Brigham and Women's Hospital, Boston. Dr Marsal's group recently described a novel T-cell subpopulation with functional implications for IBD. The group is also developing new immunological tools for better understanding the pathogenesis in IBD, for better delineation of subgroups of IBD-patients, for measuring the degree of intestinal inflammation in a stringent and objective manner, and for predicting response to targeted therapies. The group also has an interest in cancer immunology and inflammatory phenomena secondary to immune check-point inhibitor therapies, together with treatment strategies for the same. Dr Marsal is chairing the Therapy Group of SOIBD (Swedish Organisation for the study of IBD), and runs several translational and clinical IBD-projects, addressing the monitoring of IBD-patients, together with optimization of management and treatment.|
|Espen Melum is a senior scientist and group leader at the Norwegian primary sclerosing cholangitis (PSC) research center at Oslo University Hospital. He is also a physician at the Section of Gastroenterology at the Department of Transplantation Medicine. He obtained his MD and PhD degree at the University of Oslo followed by post-doctoral training at Harvard University / Brigham and Women’s Hospital under the mentorship of Richard S. Blumberg. He has taken part in deciphering the genetic underpinnings of PSC showing that all risk genes are related to immune function. His research group now focuses on understanding the immunological processes in the bile ducts using mouse models, in vitro models and more recently approaches from regenerative medicine.|
|Dr Pauliina Molander works as a Senior gastroenterologist at Helsinki University Hospital, Finland. She graduated as MD at Turku University in 1997 and specialized in Internal Medicine in 2003 and Gastroenterology in 2008 at Helsinki University Hospital. Her PhD on Assessment of TNFα blocking therapy in inflammatory bowel disease patients in deep remission was approved in Helsinki University in 2015. Her main research interest in IBD are treatment outcomes and biomarkers. She was a National representative in European Crohn’s and Colitis Organization (ECCO) 2015-2018 and served as a board member and secretary of the Finnish Society of Gastroenterology 2013-2016.|
|Randi Opheim is senior researcher and advanced nurse specialist at Department of Gastroenterology, Oslo University Hospital and Associate professor at Institute of Health and Society, University of Oslo, Norway. She has a PhD from 2014 in clinical epidemiology, including use of complementary therapies in patients with inflammatory bowel disease. Today her research is focusing on clinical epidemiology, psychosocial health, symptom burden, and health- care research. She is member of the steering committee in the IBSEN III study - a large population based prospective study of newly diagnosed patients with inflammatory bowel disease. She combines clinical work and academic profession, lecturing and supervision.|
|Dr Tim Raine MB, BChir, PhD
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Tim Raine is a consultant gastroenterologist at Addenbrooke’s Hospital, Cambridge, UK, where he leads the inflammatory bowel disease (IBD) service.
Tim has an active interest in human clinical trials in IBD and has worked as a chief investigator/principal investigator on a number of preclinical and clinical trials in IBD therapeutics, including first-in-human studies. He is the lead investigator for the major UK IASO trial in acute severe colitis. He is a member of the European Crohn’s and Colitis Organisation (ECCO) and sits on the ECCO guidelines committee; he is an author of several current ECCO guidelines and a project leader for the both Crohn’s and UC guidelines currently in development. He serves on the British Society of Gastroenterology (BSG) IBD Clinical Research Group, was awarded the BSG Young Gastroenterologist of the Year Award 2016, and is a group leader for the BSG IBD guidelines group.
He is an honorary faculty member of the Wellcome Trust Sanger Institute, Hinxton, UK. His research, funded by the Wellcome Trust, CCFA and the UK National Institute for Health Research (NIHR), focuses on understanding the regulation of the gastrointestinal immune system, in particular the immunological basis for genetic risk in IBD.
|Professor Gerhard Rogler, MD, is Professor of Gastroenterology and Hepatology and Head of the Department of Gastroenterology & Hepatology, Zürich University Hospital, Switzerland.
The main research interest of Professor Rogler is translational research to better understand the unmet needs in the IBD field, especially in terms of intestinal stricture and fistula formation. His research group has developed new models for intestinal fibrosis and achieved a novel understanding of fistula pathophysiology. Professor Rogler has authored over 500 peer-reviewed articles. He is member of the IOIBD, the governing board of ECCO and of the National Academy of Science (Leopoldina).
1999 – Student at Birkerød Gymnasium
2007 – Medical Doctor (MD) at University of Copenhagen
2009 – Medical authorization
2013 – PhD at Faculty of Health and Medical Sciences at the University of Copenhagen
2016 – Doctor of Medical Science (DMSc) at the University of Copenhagen
2007-9 – Medical and surgical rotation at Holbæk Hospital and general practice in Nkb. Sjælland
2009-12 – PhD at Dept. of Gastroenterology, Medical Section, Herlev Hospital
2012 – Dept. of Dermatology, Gentofte Hospital
2013 – Dept. of Internal Medicine, Gentofte Hospital
2013 – Postdoc at Dept. of Gastroenterology, Herlev Hospital
2014 – Dept. of Gatsroenterology, Herlev Hospoital
2014- – Resident in Internal Medicine: Gastroenterology & Hepatology (Glostrup/Riget/Herlev)
2015 – Postdoc at Dept. of Gastroenterology, Herlev Hospital
|Anders Tøttrup, Colorectal surgeon, associate professor, dr.med.sci., Consultant at Aarhus University Hospital since 2001. Specialized in IBD surgery.
Surgical training in Aarhus, Odense and Adelaide, Australia.
|Hans H. Wasmuth is a consultant surgeon at St. Olavs Hospital, Trondheim University Hospital, Norway, at the Colorectal unit. He did his degree of Dr. Philos on Ileal pouches – both on restorative proctocolectomy and continent ileostomies. Through his career since the beginning of the eighties, he has been the author on several publications on accidents and traffic injuries, in orthopaedics, in endocrine surgery, vascular surgery along with publications on neoplasia and IBD in Gastrointestinal surgery. He is member of the Norwegian Colorectal Cancer Group and Norwegian Registry of Gastrointestinal Surgery (NoRGast). He is the author of the Norwegian study of trans-anal total mesorectal excision (taTME) and to day performing studies on nevroendocrine tumores (NET) in small intestine.|